Proceeds from the Offer will be used for:
• Working capital ‒ General working capital that is sufficient for ImpediMed to achieve breakeven, including advance inventory purchases to address growth, current global chip shortages, COVID-19 related supply chain issues and transition to SOZO II
• Product enhancements ‒ SOZO II development, including weight scales and improved electronics for Renal Failure and Heart Failure
• Data and software enhancements ‒ Corporate account development including electronic health record integration and heart failure programs
• Development and commercialisation of renal failure application ‒ End stage renal disease clinical trial and US FDA clearance
I'm happy with this ... glad there were no options!
Proceeds from the Offer will be used for: • Working capital ‒...
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.3¢ |
Change
-0.002(2.11%) |
Mkt cap ! $188.1M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.3¢ | 9.3¢ | $118.4K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 78801 | 9.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.6¢ | 3900 | 1 |
View Market Depth
| Last trade - 15.59pm 19/04/2024 (20 minute delay) ? |
|
|||||
|
Last
9.3¢ |
Change
-0.002 ( 6.06 %) |
||||
| Open | High | Low | Volume | ||
| 9.6¢ | 10.0¢ | 9.3¢ | 351462 | ||
| Last updated 15.55pm 19/04/2024 ? | |||||
| IPD (ASX) Chart |